Antu Biotech’s First Quarter Report of 2026
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Securities code: 603658 Securities abbreviation: Antu Biotechnology
Zhengzhou Antu Bioengineering Co., Ltd.
2026 First Quarter Report
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder
The company's board of directors, directors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) guarantee that the financial information in the quarterly report is true, accurate and complete.
Are the first quarter financial statements audited?
□Yes √No
1. Main financial data
(1) Main accounting data and financial indicators
Unit: Yuan Currency: RMB
The same items in this reporting period compared with the same period last year.
(%)
Operating income 992,202,191.51 995,933,663.32 -0.37 Total profit 261,986,759.65 302,138,440.13 -13.29Net profit attributable to shareholders of listed companies
236,447,362.38 269,880,235.57 -12.39 profit
Deductions attributable to shareholders of listed companies 232,433,248.15 256,895,204.32 -9.52
1/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Net profit from non-recurring gains and losses
Net cash flow from operating activities
146,572,500.50 166,338,458.26 -11.88 amount
Basic earnings per share (yuan/share) 0.41 0.47 -12.77 Diluted earnings per share (yuan/share) 0.41 0.47 -12.77
Decrease of 0.47 percentage points Weighted average return on equity (%) 2.62 3.09 points The end of this reporting period compared with the end of the previous year The end of this reporting period The end of the previous year The increase or decrease at the end of the year
(%) Total assets 12,242,218,178.41 12,289,725,131.70 -0.39 All belonging to shareholders of listed companies
9,162,441,066.51 8,926,154,166.03 2.65 shareholders’ rights and interests
(2) Non-recurring profit and loss items and amounts
√Applicable □Not applicable
Unit: Yuan Currency: RMB
Non-recurring gains and losses items Amount for the current period Description of gains and losses from disposal of non-current assets, including provision for asset impairment
-1,815,344.07
prepared write-off portion
Government subsidies included in the current profit and loss, but related to the company's normal operations
Closely related to the business, in compliance with national policies and regulations, and in accordance with the determined
4,610,697.07
A government that enjoys standards and has a lasting impact on the company's profits and losses
Except for subsidies
Except for effective hedging related to the company’s normal business operations
Outside of financial affairs, non-financial enterprises hold financial assets and financial liabilities
294,492.23
Gains and losses arising from changes in fair value and disposal of financial assets and funds
Profit and loss arising from financial liabilities
Occupation of funds collected from non-financial enterprises included in current profits and losses
fee
Gains and losses from entrusting others to invest or manage assets
Profit and loss from external entrusted loans
Due to force majeure factors, such as natural disasters
asset loss
Reversal of impairment provision for accounts receivable that has been individually tested for impairment
Enterprises obtain investments from subsidiaries, associates and joint ventures
If the cost is less than when acquiring the investment, it shall enjoy the identifiable status of the invested unit.
Income from fair value of net assets
Subsidiaries resulting from business mergers under common control from the beginning of the period to the merger
Net profit and loss for the current period
2/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Gains and losses on non-monetary asset exchanges
Debt restructuring gains and losses
A one-time event that occurs because the relevant business activities of the enterprise are no longer continuing.
Expenses, such as expenses for relocating employees, etc.
Adjustments to current profits and losses due to tax, accounting and other laws and regulations
one-time impact
Shares recognized in one go due to cancellation or modification of equity incentive plan
Pay the fee
For cash-settled share-based payments, after the vesting date,
Gains and losses arising from changes in fair value of employee compensation payable
Investment real estate that adopts the fair value model for subsequent measurement
Gains and losses arising from changes in fair value of assets
Gains from transactions where the transaction price appears to be unfair
Losses arising from contingencies unrelated to the company's normal business operations
benefit
Custody fee income from entrusted operations
Other non-operating income and expenses other than the above items 1,047,963.19 Other profit and loss items that meet the definition of non-recurring profits and losses 545,969.66 Less: Amount of income tax impact 665,991.43 Amount of impact of minority shareholders’ equity (after tax) 3,672.41
Total 4,014,114.23
If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable
(3) Changes in main accounting data and financial indicators and reasons
□Applicable √Not applicable
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders. Unit: Share
Preference shareholders whose voting rights were restored at the end of the reporting period Total number of ordinary shareholders at the end of the reporting period 37,442 - Total number (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing) Shareholding ratio Pledge, mark or name of shareholder Nature of shareholder Number of shares held
Example (%) Sales restriction clause Freezing status
3/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
shares
shares
quantity quantity
Status
Zhengzhou Antu Industrial Group Co., Ltd. Domestic non-state-owned
329,445,773 57.65 0 None 0 Company Legal person
Z&F INTERNATIONAL TRADING
Overseas legal person 76,632,416 13.41 0 None 0 LIMITED
Bank of China Co., Ltd.-China
Bao Zhongzheng Medical Trading Open-end Index Others 6,324,203 1.11 0 None 0 Securities Investment Fund
Orient Securities Co., Ltd.-China
Geng Value Pioneer Equity Securities Investment Others 6,215,997 1.09 0 None 0 Fund
Agricultural Bank of China Co., Ltd.
- Dacheng Ruixiang Mixed Securities Investment Others 4,756,168 0.83 0 None 0 Fund
Hong Kong Securities Clearing Company Limited Others 3,586,382 0.63 0 None 0 Industrial and Commercial Bank of China Limited
- Dacheng Competitive Advantage Hybrid Securities Others 3,165,381 0.55 0 None 0 Investment Fund
China Everbright Bank Co., Ltd.
－Dacheng Strategy Return Hybrid Securities Others 2,242,788 0.39 0 None 0 Investment Fund
Ge Jinjia Domestic natural person 2,228,000 0.39 0 None 0 Agricultural Bank of China Co., Ltd.
-Southern S&P China A-share market is red
Others 1,641,010 0.29 0 None 0 profit and low volatility 50 trading open-end index
securities investment funds
Shareholding status of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing)
Type and number of shares held without selling restrictions
Shareholder name
Number of circulating shares Type of shares Number Zhengzhou Antu Industrial Group Co., Ltd. 329,445,773 RMB ordinary shares 329,445,773 Z&F INTERNATIONAL TRADING LIMITED 76,632,416 RMB ordinary shares 76,632,416 Bank of China Co., Ltd. - Huabao Zhongzhi Medical
6,324,203 RMB ordinary shares 6,324,203 Exchange-traded open-end index securities investment funds
Orient Securities Co., Ltd.-Zhonggeng Value Pioneer
6,215,997 RMB ordinary shares 6,215,997 Equity securities investment funds
Agricultural Bank of China Co., Ltd.-Dacheng Ruixiang
4,756,168 RMB ordinary shares 4,756,168 Hybrid securities investment funds
Hong Kong Securities Clearing Company Limited 3,586,382 RMB ordinary shares 3,586,382 Industrial and Commercial Bank of China Limited - Dacheng Competition
3,165,381 RMB ordinary shares 3,165,381 Advantage hybrid securities investment funds
China Everbright Bank Co., Ltd.-Dacheng Strategy
2,242,788 RMB ordinary shares 2,242,788 Return hybrid securities investment fund
4/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Ge Jinjia 2,228,000 RMB ordinary shares 2,228,000 Agricultural Bank of China Co., Ltd. - Southern S&P
China A-share large-cap dividend low volatility 50 trading open-end 1,641,010 RMB ordinary shares 1,641,010 Index securities investment funds
There is no related relationship between the company's controlling shareholder Zhengzhou Antu Industrial Group Co., Ltd. and the shareholder Z&F mentioned above or the same company INTERNATIONAL TRADING LIMITED. Explanation of other unknown actions of the company. Whether there is any related relationship or concerted action among the top ten shareholders of unrestricted tradable shares.
Department.
The top 10 shareholders and the top 10 unlimited shareholders Ge Jinjia hold 1,000 shares of the company through investor credit securities accounts, participate in margin financing, securities lending and refinancing through selling shareholders and hold 2,227,000 shares of the company through ordinary securities accounts, holding a total of 2,228,000 shares of the company's stock trading business (if any).
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares □ Applicable √ Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning □ Applicable √ Not applicable
3. Other reminders
Investors need to be reminded of other important information regarding the company’s operations during the reporting period.
□Applicable √Not applicable
4. Quarterly Financial Statements
(1) Types of audit opinions
□Applicable √Not applicable
(2) Financial statements
Consolidated Balance Sheet
March 31, 2026
Prepared by: Zhengzhou Antu Bioengineering Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Item March 31, 2026 Current assets on December 31, 2025:
Monetary funds 798,409,193.82 592,273,538.28 Settlement reserves
5/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Loan funds
Trading financial assets 185,183,295.00 502,095,890.45 Derivative financial assets
Notes receivable 24,480,782.70 28,174,567.90 Accounts receivable 1,110,931,371.02 1,162,522,170.02 Accounts receivable financing 3,113,284.70 4,572,024.40 Prepayments 44,975,196.41 49,797,663.64 Premiums receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 31,270,990.87 21,962,287.84 Including: interest receivable
Dividends receivable –
Buy financial assets under resale agreements
Inventory 938,241,606.73 935,451,914.51 Including: data resources
contract assets
Assets held for sale
Non-current assets due within one year
Other current assets 2,956,719,008.19 3,011,425,240.12
Total current assets 6,093,324,729.44 6,308,275,297.16 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
long-term receivables
Long-term equity investment 94,448,257.14 17,743,928.19 Other equity instrument investment 177,432,599.84 160,883,561.50 Other non-current financial assets
Investment real estate 20,530,873.94 28,430,316.25 Fixed assets 3,708,731,095.14 3,785,453,641.28 Construction in progress 77,749,222.81 61,753,743.01 Productive biological assets
oil and gas assets
Right-of-use assets 16,519,532.88 17,536,060.17 Intangible assets 187,188,421.47 168,140,468.86 Including: data resources
Development expenditure 189,003,920.37 168,668,445.66 including: data resources
Goodwill 164,648,504.26 164,648,504.26 Long-term deferred expenses 105,016,135.14 106,334,938.10 Deferred income tax assets 356,676,857.84 349,203,764.56
6/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Other non-current assets 1,050,948,028.14 952,652,462.70 Total non-current assets 6,148,893,448.97 5,981,449,834.54
Total assets 12,242,218,178.41 12,289,725,131.70 Current liabilities:
Short-term borrowings 51,288,715.64 38,341,511.47 Borrowings from the central bank
borrowing funds
Trading financial liabilities 724,794.71 Derivative financial liabilities
Notes payable 810,510,000.00 935,790,000.00 Accounts payable 558,282,019.37 585,996,694.19 Advance payments
Contract liabilities 113,264,116.85 120,091,723.13 Financial assets sold and repurchased
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
Agent underwriting securities funds
Employee benefits payable 107,637,001.36 281,498,957.67 Taxes payable 148,826,671.47 169,082,554.81 Other payables 410,725,894.59 420,612,502.45 Including: interest payable
Dividends payable
Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 10,316,368.00 10,497,968.46 Other current liabilities 67,285,696.06 66,664,439.21
Total current liabilities 2,278,136,483.34 2,629,301,146.10 Non-current liabilities:
insurance contract reserves
long term borrowing
bonds payable
Among them: preferred shares
perpetual bond
Lease liabilities 7,088,243.03 10,283,724.87 Long-term payables
Long-term employee benefits payable
Estimated liabilities 7,515,418.23 7,336,998.44 Deferred income 84,816,817.51 66,815,392.48 Deferred income tax liabilities 241,281,211.69 246,727,932.61 Other non-current liabilities 368,161,612.36 313,018,361.61 Total non-current liabilities 708,863,302.82 644,182,410.01
7/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Total liabilities 2,986,999,786.16 3,273,483,556.11 Owners’ equity (or shareholders’ equity):
Paid-in capital (or equity) 571,424,768.00 571,424,768.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 3,329,386,736.67 3,329,386,736.67 Less: treasury shares
Other comprehensive income 781,518.78 941,980.68 Special reserves
Surplus reserve 293,162,011.78 293,162,011.78 General risk reserve
Undistributed profits 4,967,686,031.28 4,731,238,668.90 Attributable to the parent company’s owner’s equity (or shares
9,162,441,066.51 8,926,154,166.03 East equity) total
Minority shareholders’ equity 92,777,325.74 90,087,409.56 Total owners’ equity (or shareholders’ equity)
9,255,218,392.25 9,016,241,575.59 total
Liabilities and Owners' Equity (or Shareholders
12,242,218,178.41 12,289,725,131.70 equity) total
Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong
consolidated income statement
January-March 2026
Prepared by: Zhengzhou Antu Bioengineering Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
- Total operating income 992,202,191.51 995,933,663.32 Including: operating income 992,202,191.51 995,933,663.32 Interest income
Premiums earned
Fee and commission income
- Total operating costs 758,254,185.72 746,443,403.96 Including: operating costs 330,992,970.52 347,853,931.15 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
8/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Reinsurance cost
Taxes and surcharges 15,916,555.61 11,685,533.86 Sales expenses 198,459,731.57 195,260,976.79 Management expenses 70,708,301.98 58,570,851.10 Research and development expenses 134,113,720.19 130,563,085.75Financial expenses 8,062,905.85 2,509,025.31Including: Interest expenses 2,725,390.30 5,583,446.15
Interest income 3,584,259.67 1,017,384.07 plus: other income 8,894,839.76 19,480,632.72 Investment income (losses are listed with "-") 19,877,467.29 23,449,847.26 Including: investments in associates and joint ventures
-45,165.05 -1,524,713.38 capital income
Financial assets measured at amortized cost
Derecognition of revenue
Exchange gains (losses are listed with "-")
Net exposure hedging income (losses are filled in with "-"
column)
Gains from changes in fair value (losses are marked with a “-”
1,201,247.29 649,979.05 fill in the column)
Credit impairment loss (losses are listed with "-") -2,867,259.07 9,988,165.74 Asset impairment losses (losses are listed with "-") 1,699,906.84 402,957.80 Asset disposal income (losses are listed with "-") - 37,110.02
Operating profit (losses are listed with "-") 262,754,207.90 303,498,951.95 plus: non-operating income 1,055,929.03 1,264,348.54 minus: non-operating expenses 1,823,377.28 2,624,860.36
Total profits (total losses are listed with "-") 261,986,759.65 302,138,440.13 Less: income tax expenses 22,849,481.09 29,058,717.66
Net profit (net loss is listed with "-") 239,137,278.56 273,079,722.47
(1) Classification by business continuity
- Net profit from continuing operations (net loss is marked with "-"
239,137,278.56 273,079,722.47 fill in the column)
- Net profit from discontinued operations (net loss is marked with "-"
Fill in the column)
(2) Classification according to ownership ownership
- Net profit (net loss) attributable to shareholders of the parent company
236,447,362.38 269,880,235.57 (please fill in the list with "-")
- Profit and loss of minority shareholders (net loss is filled in with "-"
2,689,916.18 3,199,486.90 columns)
- Net after-tax amount of other comprehensive income -160,461.90 -12,112.00
(1) Other comprehensive income attributable to owners of the parent company
-160,461.90 -12,112.00 net profit after tax
- Other comprehensive income that cannot be reclassified into profit or loss
(1) Remeasurement of changes in defined benefit plan
9/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
(2) Other comprehensive income that cannot be transferred to profit or loss under the equity method
benefit
(3) Changes in fair value of other equity instrument investments
(4) Changes in the fair value of the company’s own credit risk
- Other comprehensive income that will be reclassified into profit and loss -160,461.90 -12,112.00 (1) Other comprehensive income that can be transferred to profit and loss under the equity method
(2) Changes in fair value of other debt investments
(3) Financial assets are reclassified and included in other comprehensive income
amount of
(4) Credit impairment provisions for other debt investments
(5) Cash flow hedging reserve
(6) Translation difference of foreign currency financial statements -160,461.90 -12,112.00 (7) Others
(2) Other comprehensive income attributable to minority shareholders
net of tax
- Total comprehensive income 238,976,816.66 273,067,610.47
(1) Comprehensive income attributable to owners of the parent company
236,286,900.48 269,868,123.57 total
(2) Total comprehensive income attributable to minority shareholders 2,689,916.18 3,199,486.90
8. Earnings per share:
(1) Basic earnings per share (yuan/share) 0.41 0.47
(2) Diluted earnings per share (yuan/share) 0.41 0.47
If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan.
Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong
Consolidated Cash Flow Statement
January-March 2026
Prepared by: Zhengzhou Antu Bioengineering Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
1. Cash flow generated from operating activities:
Cash received from selling goods and providing services 1,189,097,872.31 1,121,264,719.60 Net increase in customer deposits and deposits from banks
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions
Net increase in borrowing funds
10/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
Tax refund received 773,234.86
Other cash received related to operating activities 40,724,021.70 89,678,591.42
Subtotal of cash inflows from operating activities 1,230,595,128.87 1,210,943,311.02 Cash paid for purchasing goods and receiving services 363,392,484.11 373,420,356.81 Net increase in customer loans and advances
Net increase in deposits with central banks and inter-banks
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 475,721,428.36 476,776,379.07 Various taxes and fees paid 126,410,106.27 72,647,267.29 Cash paid for other operating activities 118,498,609.63 121,760,849.59 Subtotal cash outflow from operating activities 1,084,022,628.37 1,044,604,852.76
Net cash flow generated from operating activities 146,572,500.50 166,338,458.26
2. Cash flow generated from investing activities:
Cash received from recovery of investment 3,450,961.66
Cash received from investment income 2,235,870.00
Disposal of fixed assets, intangible assets and other long-term
Net cash amount recovered from period 6,000.00 assets
Received from disposal of subsidiaries and other business units
net cash
Other cash received related to investing activities 2,222,136,910.87 10,018,513.89
Subtotal of cash inflows from investing activities 2,227,823,742.53 10,024,513.89 Purchase and construction of fixed assets, intangible assets and other long-term assets
133,159,505.15 146,794,114.20 Cash paid for assets
Cash paid for investment 88,499,494.00 7,500,000.00 Net increase in pledged loans
Obtain payment from subsidiaries and other business units
net cash
Other cash payments related to investing activities 1,836,927,142.31 236,722,718.03 Subtotal of cash outflows from investing activities 2,058,586,141.46 391,016,832.23
Net cash flow generated from investing activities 169,237,601.07 -380,992,318.34
3. Cash flow generated from financing activities:
Cash received from investment 14,455,000.00, of which: subsidiaries received investment from minority shareholders
14,455,000.00 in cash
Cash received from borrowings 3,000,000.00 291,970,786.89 Cash received from other financing activities 160,850,000.00 439,770,402.48
Subtotal of cash inflows from financing activities 163,850,000.00 746,196,189.37 Cash paid to repay debts 488,000,000.00
11/12
Zhengzhou Antu Bioengineering Co., Ltd. 2026 First Quarter Report
Distribution of dividends, profits or repayment of interest payments
283,730.83 3,463,420.84 cash
Including: shares paid by subsidiaries to minority shareholders
Profit, profit
Cash payments related to other financing activities 265,573,745.22 275,840,504.05 Subtotal of cash outflows from financing activities 265,857,476.05 767,303,924.89
Net cash flow generated from financing activities -102,007,476.05 -21,107,735.52
4. The impact of exchange rate changes on cash and cash equivalents
-7,662,969.99 3,228,949.87 impact
- Net increase in cash and cash equivalents 206,139,655.53 -232,532,645.73
Add: Balance of cash and cash equivalents at the beginning of the period 582,870,723.61 452,058,348.81
- Balance of cash and cash equivalents at the end of the period 789,010,379.14 219,525,703.08
Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong
(3) The first implementation of new accounting standards or standard interpretations starting in 2026 will involve adjustments to the financial statements at the beginning of the year of first implementation.
□Applicable √Not applicable
Announcement hereby
Board of Directors of Zhengzhou Antu Bioengineering Co., Ltd. April 21, 2026
12/12